Radar · Life Sciences Platforms and Tools in United States
Best Life Sciences Platforms and Tools Companies in United States
The 2973 best Life Sciences Platforms and Tools companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nektar.
By Riya SenguptaFinancials
2973companies tracked
$32.9Bdisclosed funding
3unicorns
1383have raised
Ranking the best Life Sciences Platforms and Tools companies in the United States, this directory tracks 2,973 firms carrying $32.9B in disclosed funding across three unicorns. The revenue picture is where things get interesting. Across 32 validated filers, median revenue sits at $24M with a modest 2% YoY growth rate, but the combined pool reaches $5.6B, which tells you the distribution is anything but even. Illumina pulled $1.1B at 5% growth. Life Technologies Corp logged $963M. Beckman Coulter hit $895M, and Bruker Corp added $823M at 3% growth. Four companies alone account for a substantial slice of that pool.
The profitability gap is just as striking. Sector median net income is $5M, yet Bio-Rad Laboratories posted $760M, a figure 162 times that median. I find that multiplier genuinely clarifying, because it separates the platform builders with durable economics from the earlier-stage filers still burning toward scale. Cellares ($355M funded) and Alamar Biosciences ($250M) are among the most-funded names here, with HHS, NIH, and the National Science Foundation showing up as the most active investors. Hot themes driving fresh capital include drug repurposing AI, diagnostic biotechnology, and clinical trial outsourcing. So the funding momentum and the revenue concentration are both pointing the same direction: scale compounds fast at the top of this sector.
Sources & further reading
- Gartner Predicts 75 Percent of Analytics Content to Use GenAI for Enhanced Conte
- Top 13 BI and Reporting Services Providers
- Pfizer, Pharmacia Merger: Will It Help Or Hurt Biotech Sector?
FLIAR INTELLIGENCE · LIFE SCIENCES PLATFORMS AND TOOLS × UNITED STATES
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
68%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2013median founding year
386kcombined LinkedIn audience
30%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences Platforms and Tools companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences 🦄 Developer of benchtop DNA sequencer for research applications 84Innovation top 10%Patents top 13%Funding top 16%Moat top 22% All 11 signals ▾Innovationtop 10% Patentstop 13% Fundingtop 16% Moattop 22% Markettop 35% Growthtop 35% Talenttop 38% Producttop 41% Techtop 45% Globalbottom 47% Newsbottom 24% Innovation: 554 patents (top 4% of patent-holders) · 469 filings since 2022 vs 85 in 2017-21 Patents: 554 patents matched (strict assignee match) · 469 filings since 2022 vs 85 in 2017-21 rank vs industry peers · Fliar Intelligence Index 84/100 | $678M | 23 mo ago | 318 | Michael Previte CTO | HubSpot CMS HubVimeoAnimate.css+20 | — | 554 patents Advanced optical flow cells, reagents, and data processing for next‑gen DNA sequencing | 1 job opening |
| 2 | Cellares Manufacturer of a medical device for cell-based therapy 82Funding top 15%News top 19%Innovation top 23%Growth top 25% All 11 signals ▾Fundingtop 15% Newstop 19% Innovationtop 23% Growthtop 25% Patentstop 27% Moattop 28% Partnerstop 31% Talenttop 35% Markettop 41% Techtop 43% Globalbottom 39% Funding: Raised $355M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 25 tracked, 4 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 82/100 | $355M | 4 mo ago | 154 | Fabian Gerlinghaus Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+32 | 9 signals ▲200% Leadership · Contracts · Funding | 89 patents Patents concentrated in transport & manufacturing processes | 1 partnership · 1 expansion · 1 award |
| 3 | Avalyn Pharma Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis 57Funding top 14%Growth top 30%News top 30%Moat top 31% All 7 signals ▾Fundingtop 14% Growthtop 30% Newstop 30% Moattop 31% Techtop 40% Globalbottom 39% Marketbottom 36% Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $289M | 10 mo ago | 24 | — | WordPressApple iCloud MailMySQL+25 | 5 signals ▲25% IPO | — | — |
| 4 | Dewpoint Therapeutics Developer of small molecule based therapeutics 53Funding top 17%Moat top 31%Talent top 38%News top 41% All 7 signals ▾Fundingtop 17% Moattop 31% Talenttop 38% Newstop 41% Markettop 45% Globalbottom 45% Techbottom 32% Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $287M | 9 mo ago | 147 | Richard Young Co-Founder | BreakdanceWordPressApple iCloud Mail+13 | — | — | 1 job opening |
| 5 | Alamar Biosciences Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels 67News top 18%Funding top 19%Growth top 30%Moat top 31% All 9 signals ▾Newstop 18% Fundingtop 19% Growthtop 30% Moattop 31% Talenttop 35% Techtop 37% Markettop 44% Fin. healthbottom 46% Globalbottom 36% News: 15 BI events in 12 mo (of 30 tracked, 5 types) · +67% YoY Funding: Raised $250M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $250M | 5 mo ago | 83 | Steve Chen Co-Founder | WordPressApple iCloud MailMicrosoft 365+37 | 15 signals ▲67% IPO · Funding · Leadership | — | 1 internship · 1 launch · 1 expansion |
| 6 | Opentrons 🦄 Developer of pipetting robot for lab automation 84Funding top 18%Market top 26%Moat top 26%Growth top 31% All 8 signals ▾Fundingtop 18% Markettop 26% Moattop 26% Growthtop 31% Techtop 32% Globaltop 37% Talenttop 38% Newstop 44% Funding: Raised $241M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Market: 177 employees (top 6% of Life Sciences Platforms and Tools) · Top-1,000,000 web property rank vs industry peers · Fliar Intelligence Index 84/100 | $241M | 6 mo ago | 177 177 → 196 (+11%) · sector median +18% | James Atwood CEO | Cart FunctionalityBigCommerceWordPress+50 | — | — | 3 launchs |
| 7 | Emulate Developer of in vitro models for drug development 78Funding top 15%Patents top 25%Moat top 26%Innovation top 34% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 26% Innovationtop 34% Techtop 34% Growthtop 40% Markettop 45% AItop 45% Globalbottom 49% Newsbottom 22% Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $225M | 8 mo ago | 103 103 → 71 (-31%) · sector median +18% | — | WordPress Block EditorWordPressApple iCloud Mail+38 | — | 479 patents Microfluidic organ‑on‑chip platforms for tissue modeling and drug screening | 1 job opening |
| 8 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 21 mo ago | 54 54 → 75 (+39%) · sector median +18% | Jonathan Romanowsky Co-Founder and Chief Business Officer | WordPressMySQLPHP+24 | — | 52 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 9 | Life Biosciences Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases 53Funding top 16%Growth top 28%Moat top 31%News top 43% All 7 signals ▾Fundingtop 16% Growthtop 28% Moattop 31% Newstop 43% Techtop 49% Globalbottom 39% Marketbottom 33% Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $150M | 2 mo ago | 14 14 → 27 (+93%) · sector median +18% | — | WordPressMySQLPHP+20 | — | — | — |
| 10 | PrognomiQ Developer of tests for the detection and treatment of cancer and other diseases 57Funding top 17%Patents top 25%Moat top 28%Innovation top 31% All 9 signals ▾Fundingtop 17% Patentstop 25% Moattop 28% Innovationtop 31% Talenttop 38% Techtop 44% Globalbottom 40% Marketbottom 34% Newsbottom 18% Funding: Raised $135M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 70 patents matched (strict assignee match) · 68 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $135M | 5 mo ago | 24 24 → 44 (+83%) · sector median +18% | Philip Ma Co-Founder & CEO | WordPressMarkerApple iCloud Mail+30 | — | 70 patents Patents concentrated in computing, sensing & instrumentation | — |
| 11 | Mission Bio Provider of single cell multiomics platform for genotypic and phenotypic analysis 82Funding top 18%Tech top 21%Innovation top 25%Product top 25% All 10 signals ▾Fundingtop 18% Techtop 21% Innovationtop 25% Producttop 25% Talenttop 28% Moattop 31% Growthtop 37% Markettop 44% Globalbottom 39% Newsbottom 27% Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 10 mo ago | 109 109 → 89 (-18%) · sector median +18% | Adam Sciambi Co-Founder & Chief Technology Officer | SanityTurbopackSentry+34 | — | — | 1 launch · 1 partnership |
| 12 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 12 mo ago | 54 54 → 61 (+13%) · sector median +18% | Joseph Victor President & CEO | — | — | 266 patents Advanced fluorescence microscopy and spectral imaging hardware for multiplexed cellular analysis | 1 launch |
| 13 | Culture Biosciences Provider of biomanufacturing hardware and software tools for research purposes 67Funding top 20%Product top 25%Growth top 26%Moat top 31% All 10 signals ▾Fundingtop 20% Producttop 25% Growthtop 26% Moattop 31% Innovationtop 34% Talenttop 34% Techtop 45% Newsbottom 42% Marketbottom 41% Globalbottom 37% Funding: Raised $107M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Product: 6 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 67/100 | $107M | 6 mo ago | 35 35 → 67 (+91%) · sector median +18% | Chris Williams CEO | WebflowSwipercore-js+20 | — | — | — |
| 14 | Debut Provider and manufacturer of enzymes for biotherapeutic creation and modification 35Funding top 21%Moat top 31%News top 34%Tech bottom 49% All 7 signals ▾Fundingtop 21% Moattop 31% Newstop 34% Techbottom 49% Talentbottom 48% Globalbottom 45% Marketbottom 31% Funding: Raised $106M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 35/100 | $106M | 9 mo ago | 18 | Gregory Weiss Co-Founder | WebflowSentryApple iCloud Mail+15 | 3 signals Funding · Leadership | — | 1 partnership |
| 15 | Antheia Genetically engineered yeast cells to produce medicinal products 64Funding top 20%Patents top 25%Moat top 28%Innovation top 34% All 12 signals ▾Fundingtop 20% Patentstop 25% Moattop 28% Innovationtop 34% Producttop 35% Growthtop 36% Talenttop 40% Techtop 45% Newstop 45% Partnerstop 45% Globalbottom 47% Marketbottom 45% Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $96M | 4 mo ago | 50 50 → 66 (+32%) · sector median +18% | Christina Smolke Co-Founder & CEO | WordPressMySQLPHP+28 | 4 signals Leadership · Funding | 82 patents Biotechnological production and optimization of opioid alkaloids (benzylisoquinoline and morphinan) | 2 job openings |
| 16 | Arzeda Developer of enzyme design technology to bridge the gap by creating synthetic enzymes 80Funding top 20%Patents top 21%Innovation top 26%Growth top 28% All 11 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 26% Growthtop 28% Moattop 28% Talenttop 28% Producttop 40% Markettop 45% Partnerstop 45% Globalbottom 42% Newsbottom 18% Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $91M | 9 mo ago | 60 60 → 78 (+30%) · sector median +18% | David Baker Co-Founder | — | — | 85 patents Biocatalytic production and modification of stevia sweeteners and keto‑sugar derived chemicals | 1 partnership |
| 17 | RedShift Provider of tools for analytical testing 57Moat top 22%Funding top 25%Product top 26%Growth top 32% All 10 signals ▾Moattop 22% Fundingtop 25% Producttop 26% Growthtop 32% Techtop 34% Innovationtop 35% Newstop 41% Talentbottom 49% Marketbottom 34% Globalbottom 32% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $89.4M across 12 rounds · 12 rounds over 20 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $89M | 12 mo ago | 28 28 → 26 (-7%) · sector median +18% | Eugene Ma Co-founder & CTO | Webflowanime.jsGSAP+23 | — | — | — |
| 18 | Xilis Developer of drug discovery and precision therapy platform for oncology 53Patents top 21%Moat top 21%Innovation top 22%Funding top 26% All 9 signals ▾Patentstop 21% Moattop 21% Innovationtop 22% Fundingtop 26% Talentbottom 49% Marketbottom 46% Globalbottom 42% Techbottom 29% Newsbottom 22% Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $89M | 14 mo ago | 72 | Hans Clevers Co-Founder | WordPressMySQLPHP+16 | — | 97 patents Micro-organosphere generation, manipulation, and drug testing via advanced microfluidic platforms | — |
| 19 | SpectronRx Provider of therapeutic and diagnostic isotope solutions 45Funding top 21%Growth top 28%Moat top 45%News top 46% All 11 signals ▾Fundingtop 21% Growthtop 28% Moattop 45% Newstop 46% Markettop 47% Talentbottom 49% Patentsbottom 41% Techbottom 37% Globalbottom 35% Partnersbottom 35% Innovationbottom 23% Funding: Raised $85.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 2 mo ago | 93 | John Zehner CEO | WordPressMySQLPHP+14 | — | 2 patents Radium‑226 extraction from phosphogypsum waste streams | — |
| 20 | Ansa Biotechnologies Provider of DNA synthesis technology using enzymes 74Growth top 26%Funding top 27%Patents top 27%Moat top 32% All 11 signals ▾Growthtop 26% Fundingtop 27% Patentstop 27% Moattop 32% Innovationtop 33% Newstop 38% Producttop 40% Markettop 41% Techtop 43% Talenttop 45% Globalbottom 47% Growth: Headcount 159 → 253 (+59%) across vintages · Fresh capital in last 24 mo Funding: Raised $82.0M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $82M | 8 mo ago | 253 | Sebastian Palluk Co-Founder & CTO | WordPress Block EditorWordPressApple iCloud Mail+27 | 3 signals Funding · Leadership | 32 patents Enzymatic nucleic acid synthesis and polymerase engineering for synthetic biology applications | 1 job opening · 1 award |
| 21 | MBF Bioscience Microscopy solutions for neuroscience, medical education, and biomedical research 53Funding top 33%Growth top 35%Tech top 48%Market bottom 48% All 5 signals ▾Fundingtop 33% Growthtop 35% Techtop 48% Marketbottom 48% Globalbottom 33% Funding: Raised $78.3M across 30 rounds · 30 rounds over 22 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $78M | 15 mo ago | 42 | — | WordPressApple iCloud MailMicrosoft 365+28 | — | — | 1 launch · 1 award |
| 22 | Hemanext Developer of technologies to store blood and its products 67Patents top 15%Innovation top 17%Moat top 26%Funding top 28% All 10 signals ▾Patentstop 15% Innovationtop 17% Moattop 26% Fundingtop 28% Growthtop 40% Talenttop 43% Techtop 47% Marketbottom 46% Globalbottom 36% Newsbottom 31% Patents: 265 patents matched (strict assignee match) · 194 filings since 2022 vs 65 in 2017-21 Innovation: 265 patents (top 8% of patent-holders) · 194 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $67M | 11 mo ago | 53 53 → 36 (-32%) · sector median +18% | Martin Cannon Founder | WordPressMySQLPHP+19 | — | 265 patents Patents concentrated in health & consumer products | — |
| 23 | Recombinetics Developer of gene repair and gene-editing technology to create animal models 35Moat top 19%Funding top 30%Patents top 32%Product top 36% All 10 signals ▾Moattop 19% Fundingtop 30% Patentstop 32% Producttop 36% Innovationtop 37% Globalbottom 42% Growthbottom 41% Techbottom 36% Marketbottom 33% Newsbottom 22% Moat: Editorial + unicorn rating 8/10 · IP moat: 242 patents Funding: Raised $66.8M across 25 rounds · 25 rounds over 15 yrs (1.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $67M | 14 mo ago | 29 29 → 17 (-41%) · sector median +18% | — | WordPressMySQLPHP+17 | — | 242 patents Livestock genome engineering via pluripotent stem cells and non-meiotic allele introgression | — |
| 24 | Cytotheryx Developer of human hepatocytes for research and clinical applications 29Moat top 30%Patents top 37%Funding top 38%Innovation top 41% All 7 signals ▾Moattop 30% Patentstop 37% Fundingtop 38% Innovationtop 41% Talentbottom 49% Globalbottom 35% Marketbottom 25% Moat: IP moat: 14 patents · Soonicorn Patents: 14 patents matched (strict assignee match) · 14 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $60M | 5 mo ago | 12 | John Swart Chief Executive Officer | — | — | 14 patents Engineered human hepatocyte production, genetic modification, and biliary delivery platforms | — |
| 25 | Spatial Genomics Developer of multiplexed assays for drug development 24Moat top 22%Funding top 32%Talent bottom 49%Tech bottom 47% All 6 signals ▾Moattop 22% Fundingtop 32% Talentbottom 49% Techbottom 47% Globalbottom 32% Marketbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $56.0M across 7 rounds · 7 rounds over 4 yrs (1.8/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $56M | 12 mo ago | 21 | Drew Kennedy Co-Founder | WordPressMySQLMariaDB+17 | — | — | — |
| 26 | Lygos Manufacturer of green acids from microbes 64Moat top 26%Patents top 27%Funding top 30%Growth top 31% All 9 signals ▾Moattop 26% Patentstop 27% Fundingtop 30% Growthtop 31% Innovationtop 33% Techtop 40% Talentbottom 49% Marketbottom 48% Globalbottom 42% Moat: Editorial + unicorn rating 8/10 · IP moat: 111 patents Patents: 111 patents matched (strict assignee match) · 56 filings since 2022 vs 49 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $52M | 14 mo ago | 63 | Eric Steen CEO & Co-founder | Builder.ioApple iCloud MailGoogle Workspace+21 | — | 111 patents Patents concentrated in chemistry & materials | — |
| 27 | Therapeutic Systems Research Laboratories Preclinical CRO driving smarter drug development with integrated services and scientific clarity 32Funding top 37%Innovation top 39%Product top 46%Talent bottom 49% All 7 signals ▾Fundingtop 37% Innovationtop 39% Producttop 46% Talentbottom 49% Techbottom 44% Globalbottom 29% Marketbottom 28% Funding: Raised $51.6M across 32 rounds · 32 rounds over 23 yrs (1.4/yr) Innovation: 9 product lines rank vs industry peers · Fliar Intelligence Index 32/100 | $52M | 13 mo ago | 20 | Elke Lipka President and CEO | Squarespace CommerceSquarespaceTypeScript+12 | — | — | — |
| 28 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | 25 25 → 31 (+24%) · sector median +18% | Irene Yuan Co-Founder & Executive Vice President | — | — | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 29 | NanoMosaic Manufacturer of system for early disease detection and prognosis 53Innovation top 32%Patents top 33%Funding top 34%Moat bottom 49% All 6 signals ▾Innovationtop 32% Patentstop 33% Fundingtop 34% Moatbottom 49% Marketbottom 46% Globalbottom 35% Innovation: 19 patents (top 52% of patent-holders) · 14 filings since 2022 vs 5 in 2017-21 Patents: 19 patents matched (strict assignee match) · 14 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $41M | 7 mo ago | 37 | — | — | — | 19 patents Nanostructured biosensors for viral particle detection and unbiased proteomic analysis | — |
| 30 | Electronic Bio Provider of nanotech-based DNA sequencing solutions 10Funding top 37%Talent bottom 45%Global bottom 29%Market bottom 24% All 5 signals ▾Fundingtop 37% Talentbottom 45% Globalbottom 29% Marketbottom 24% Techbottom 15% Funding: Raised $40.7M across 49 rounds · 49 rounds over 19 yrs (2.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $41M | 12 mo ago | 15 | Eric Ervin President and CEO | — | — | — | — |
| 31 | Avalon Globocare Developer of diagnostics using exosome technology 21News top 26%Funding top 34%Patents top 45%Growth top 47% All 10 signals ▾Newstop 26% Fundingtop 34% Patentstop 45% Growthtop 47% Innovationbottom 48% Moatbottom 44% Globalbottom 40% Techbottom 36% Fin. healthbottom 26% Marketbottom 22% News: 14 BI events in 12 mo (of 21 tracked, 5 types) · 9 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $36.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $37M | 3 mo ago | 6 | — | BootstrapApache HTTP ServerKlaro+13 | 14 signals M&A · Announcements · Funding | 16 patents Engineered soluble GPCR Fc-fusion proteins and S-layer emulsome delivery systems | — |
| 32 | Arunabio Developer of a neural exosome platform to design therapeutics for the treatment of neurodegenerative diseases 42Funding top 29%Talent bottom 49%Market bottom 47%Global bottom 37% All 5 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 47% Globalbottom 37% Newsbottom 18% Funding: Raised $33.1M across 20 rounds · 20 rounds over 9 yrs (2.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 42/100 | $33M | 10 mo ago | 40 | Steven Stice Co-Founder Chief Scientific Officer | — | — | — | — |
| 33 | Indoor Biotechnologies Allergen expertise: purified allergens, test kits, testing services, and contract research 37Tech top 32%Moat top 38%Funding top 42%Growth top 45% All 10 signals ▾Techtop 32% Moattop 38% Fundingtop 42% Growthtop 45% Producttop 46% Talentbottom 49% Patentsbottom 45% Innovationbottom 42% Globalbottom 40% Marketbottom 29% Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Alb, Amazon S3 Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $33M | 9 mo ago | — | Martin Chapman Chief Executive Officer | WordPressAlgoliaMySQL+29 | — | 9 patents Patents concentrated in chemistry & materials | — |
| 34 | Trethera Developer of small molecule cancer therapeutics that target DNA replication and integrity 29Funding top 30%Patents top 37%Moat top 37%Product top 41% All 9 signals ▾Fundingtop 30% Patentstop 37% Moattop 37% Producttop 41% Innovationtop 42% Techtop 47% Talentbottom 49% Globalbottom 33% Marketbottom 18% Funding: Raised $31.0M across 20 rounds · 20 rounds over 11 yrs (1.8/yr) Patents: 15 patents matched (strict assignee match) · 15 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 8 mo ago | 3 | Ken Schultz Chairman & CEO | WordPressMySQLPHP+16 | — | 15 patents Patents concentrated in health & consumer products | — |
| 35 | OmniAb Therapeutic antibody discovery company providing diverse antibody repertoires and cutting-edge screening… 48Patents top 25%Innovation top 33%Funding top 36%Tech top 42% All 10 signals ▾Patentstop 25% Innovationtop 33% Fundingtop 36% Techtop 42% Markettop 46% Moattop 48% Globalbottom 38% Fin. healthbottom 38% Growthbottom 33% Newsbottom 18% Patents: 30 patents matched (strict assignee match) · 29 filings since 2022 vs 1 in 2017-21 Innovation: 30 patents (top 42% of patent-holders) · 29 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $30M | 9 mo ago | 95 | — | WordPressApple iCloud MailMicrosoft 365+33 | — | 30 patents Therapeutic antibodies for immune checkpoints and viral targets, plus APOL1 small‑molecule inhibitors. | — |
| 36 | Kiyatec Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to… 32Product top 25%Moat top 32%Funding top 37%Innovation top 48% All 9 signals ▾Producttop 25% Moattop 32% Fundingtop 37% Innovationtop 48% Patentstop 50% Marketbottom 40% Globalbottom 37% Techbottom 36% Newsbottom 21% Product: 5 distinct product lines · Company stage: Series C Moat: Editorial + unicorn rating 7/10 · IP moat: 36 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $29M | 7 mo ago | 28 | — | — | — | 36 patents In vitro cancer drug screening platforms using 3D tumor bioreactors for dosing optimization | — |
| 37 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | 48 | Paul Roma Co-Founder | — | — | — | — |
| 38 | Phylos Bioscience Developer of cannabis F1 hybrid seeds and natural THC products 42Funding top 26%Moat top 39%Talent top 41%Partners top 45% All 9 signals ▾Fundingtop 26% Moattop 39% Talenttop 41% Partnerstop 45% Techtop 46% Marketbottom 46% Growthbottom 38% Globalbottom 37% Newsbottom 17% Funding: Raised $28.2M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $28M | 5 mo ago | 61 61 → 50 (-18%) · sector median +18% | Nishan Karassik Chief Innovation Officer | PrismicNode.jsNginx+14 | — | — | 4 launchs |
| 39 | Healionics Manufacturer of synthetic biomaterials and implantable medical devices 27Talent top 15%Moat top 25%Funding top 35%Patents top 42% All 9 signals ▾Talenttop 15% Moattop 25% Fundingtop 35% Patentstop 42% Innovationbottom 47% Globalbottom 40% Techbottom 32% Marketbottom 20% Newsbottom 18% Talent: Analyst team rating 5/5 Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $27M | 6 mo ago | 10 | — | WordPressMySQLPHP+15 | — | 42 patents Implantable vascular grafts and porous ocular drug‑delivery devices for eye disease treatment | — |
| 40 | BrightSpec Provider of molecular rotational resonance spectroscopy technology 32Moat top 25%Innovation top 35%Patents top 36%Funding top 37% All 8 signals ▾Moattop 25% Innovationtop 35% Patentstop 36% Fundingtop 37% Talentbottom 49% Globalbottom 40% Techbottom 33% Marketbottom 27% Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents Innovation: 31 patents (top 41% of patent-holders) · 18 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $25M | 10 mo ago | 13 13 → 26 (+100%) · sector median +18% | Dave Mcdaniel Co-founder and Chief Software Officer | — | — | 31 patents Analytical instruments for low‑volatility sample collection and molecular rotational resonance spectroscopy | — |
| 41 | Virtici Transforms innovations into life-changing medical products through leadership, space, and funding 11Funding top 42%Global bottom 35%Patents bottom 29%Innovation bottom 19% All 4 signals ▾Fundingtop 42% Globalbottom 35% Patentsbottom 29% Innovationbottom 19% Funding: Raised $24.2M across 27 rounds · 27 rounds over 14 yrs (1.9/yr) Global: Single-market focus (United States) rank vs industry peers · Fliar Intelligence Index 11/100 | $24M | 10 mo ago | 9 | — | — | — | 7 patents Inducing immune tolerance to peptide antigens for allergy and immune activation therapies | — |
| 42 | Pumpkinseed Developer of protein sequencing technology using silicon photonics and machine learning 67Talent top 35%Funding top 36%AI top 45%Global bottom 33% All 4 signals ▾Talenttop 35% Fundingtop 36% AItop 45% Globalbottom 33% Talent: 3 named leaders on record Funding: Raised $20.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $20M | 1 mo ago | — | Jennifer Dionne Co-Founder | — | — | — | — |
| 43 | NanoScope Technologies Instruments and devices for biomedical application 13Funding top 43%Market bottom 32%Global bottom 29% All 3 signals ▾Fundingtop 43% Marketbottom 32% Globalbottom 29% Funding: Raised $17.6M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) Market: 18 employees rank vs industry peers · Fliar Intelligence Index 13/100 | $18M | 8 mo ago | 18 | — | — | — | — | — |
| 44 | Lectenz Develops tools for biomarker discovery 35Innovation top 20%Funding top 44%Talent top 45%Product top 46% All 7 signals ▾Innovationtop 20% Fundingtop 44% Talenttop 45% Producttop 46% Techbottom 36% Globalbottom 29% Marketbottom 13% Innovation: 5 product lines Funding: Raised $15.3M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $15M | 8 mo ago | 6 | Robert Woods President | — | — | — | 1 partnership |
| 45 | iSpecimen Provider of a biorepository of human clinical specimens 24News top 30%Tech top 36%Funding top 42%Partners top 45% All 9 signals ▾Newstop 30% Techtop 36% Fundingtop 42% Partnerstop 45% Growthbottom 44% Moatbottom 41% Marketbottom 38% Globalbottom 32% Fin. healthbottom 22% News: 10 BI events in 12 mo (of 51 tracked, 5 types) · +0% YoY Tech: 38 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 24/100 | $12M | 1 mo ago | 75 | — | WordPressMySQLPHP+24 | 10 signals Funding · Announcements | — | — |
| 46 | H3D High-performance imaging spectrometers revolutionizing gamma-ray source identification and localization 35AI top 15%Patents top 46%Funding top 49%Talent bottom 49% All 9 signals ▾AItop 15% Patentstop 46% Fundingtop 49% Talentbottom 49% Productbottom 48% Globalbottom 41% Marketbottom 39% Innovationbottom 39% Techbottom 35% AI: Holds AI/ML patents (G06N-family CPC) Patents: 19 patents matched (strict assignee match) · 6 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 5 mo ago | 31 | Weiyi Wang Research And Development Director | Apple iCloud MailUbuntuYouTube+4 | — | 19 patents Coded-aperture radiation imaging and 3D source localization systems | 1 launch |
| 47 | Exum Provider of tools and instruments for research 8Funding top 45%Tech top 45%Growth bottom 42%Global bottom 32% All 7 signals ▾Fundingtop 45% Techtop 45% Growthbottom 42% Globalbottom 32% Moatbottom 22% Marketbottom 16% Fin. healthbottom 8% Funding: Raised $9.9M across 8 rounds · 8 rounds over 7 yrs (1.1/yr) Tech: 23 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 8/100 | $10M | 6 mo ago | 15 | — | WebflowYouTubejQuery-pjax+20 | — | — | 1 launch |
| 48 | Blank Bio Developer of RNA foundation models for precision medicine research applications 60Talent top 28%Funding top 35%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 35% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $7M | 1 mo ago | — | Jonathan Hsu Co-Founder & CEO | — | — | — | — |
| 49 | 10x Science Provider of AI-native protein characterization platform for biopharma 37Talent top 28%AI top 35%Funding top 42%Tech bottom 46% All 6 signals ▾Talenttop 28% AItop 35% Fundingtop 42% Techbottom 46% Globalbottom 33% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-driven, ai-native rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 1 mo ago | — | Vishnu Tejus Co-Founder & CTO | Three.jsRadix UIElement UI+11 | — | — | — |
| 50 | Inso Bio Developer of a microfluidic-based automated device used for sample preparation 13Talent top 38%Funding top 47%Global bottom 39%Market bottom 18% All 4 signals ▾Talenttop 38% Fundingtop 47% Globalbottom 39% Marketbottom 18% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $2.8M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 13/100 | $3M | 3 mo ago | 4 | Harvey Tian Co-Founder & CEO | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in United States
#1
Series D · Boston, Massachusetts · founded 2017 · 14 employees$150.2Mraised▾
Series D · Boston, Massachusetts · founded 2017 · 14 employees
Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%Growth
top 28%Moat
top 31%News
top 43%Tech
top 49%Global
bottom 39%Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) · Last round Series D (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 13k LinkedIn followers — 3.5% of this cohort's audience
Funding rounds
- Apr 2026Series D$80M
- Nov 2025Series C$31M
- Jan 2022Series C$82M
- Jun 2020Series B$18.2M
Investors
Alpha Wave Global, The Longevity Fund, National Science Foundation, Abundance Partners, Wynwood Projects, Globalive Capital
Tech stack
CloudflareCloudflare Bot ManagementCookieyesGodaddyGoogle AnalyticsGoogle Hosted Libraries
#2
Series D · San Francisco, California · founded 2019 · 154 employees$355Mraised▾
Series D · San Francisco, California · founded 2019 · 154 employees
Manufacturer of a medical device for cell-based therapy. The company offers Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. It also, offers software suite for cell therapy modalities.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 15%News
top 19%Innovation
top 23%Growth
top 25%Patents
top 27%Moat
top 28%Funding: Raised $355M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jan 2026)
News: 9 BI events in 12 mo (of 25 tracked, 4 types) · +200% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Innovation: 89 patents (top 32% of patent-holders) · 83 filings since 2022 vs 6 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 31k LinkedIn followers — 8.1% of this cohort's audience · 94 engagements/post (3.0× cohort median)
Activity (LinkedIn): 1 partnerships · 1 awards · 1 expansions (incl. FDA) announced in 12 mo
Funding rounds
- Jan 2026Series D$257M
- Aug 2023Series C$255M
- Apr 2021Series B$82M
- Aug 2019Series A$18M
Founders & team
Investors
8VC, EcoR1, Eclipse, Decheng Capital, Skyviews Life Science, Koch Disruptive Technologies
Tech stack
Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookieyes
#3
Public · Fremont, California · founded 2018 · 83 employees$250Mraised▾
Public · Fremont, California · founded 2018 · 83 employees
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
News
top 18%Funding
top 19%Growth
top 30%Moat
top 31%Talent
top 35%Tech
top 37%News: 15 BI events in 12 mo (of 30 tracked, 5 types) · +67% YoY · 11 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $250M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Jan 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 30k LinkedIn followers — 7.9% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series C$50M
- Feb 2024Series C$100M
- Sep 2021Series B$80M
- Jul 2020Grant (prize money)$321.9K
Founders & team
Investors
Sands Capital, Sherpa Healthcare Partners, Morningside, Samsara BioCapital, Qiming Venture Partners, Illumina Ventures
Tech stack
Apple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCookieyesCore-Js
#4
Series C · Brooklyn, New York · founded 2013 · 177 employees$240.6Mraised▾
Series C · Brooklyn, New York · founded 2013 · 177 employees
Developer of pipetting robot for lab automation. The company's product OT-2 personal pipetting robot uses manual micro-pipettes to transfer fluids and automates the repetitive benchwork associated with lab activities. It also has scalable hardware and software and is developed in an open-source manner.
Fliar Intelligence Index™ 84how this company ranks against its industry peers
Funding
top 18%Market
top 26%Moat
top 26%Growth
top 31%Tech
top 32%Global
top 37%Funding: Raised $241M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series C (Nov 2025)
Market: 177 employees (top 6% of Life Sciences Platforms and Tools) · Top-1,000,000 web property · Unicorn (valued $1.8B)
Moat: Editorial + unicorn rating 9/10 · Unicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 6.3% of this cohort's audience
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Nov 2025Series C$20.1M
- Sep 2021Series C$200M
- Aug 2020Series B$20.6M
- Nov 2019Seed$2.2M
Founders & team
Investors
HAX, Khosla Ventures, Y Combinator, Lerer Hippeau, SoftBank Group, Sands Capital
Tech stack
AlgoliaAlpine.JsAmazon S3Amazon Web ServicesApple Icloud MailBigcommerce
#5
Series C · Indianapolis, Indiana · founded 2004 · 93 employees$85Mraised▾
Series C · Indianapolis, Indiana · founded 2004 · 93 employees
SpectronRx is a provider of therapeutic and diagnostic isotope solutions. It provides radionuclides and custom theranostic contract manufacturing like monoclonal antibody labelling, peptides, radiolabeling of molecules and chemical entities, and aptamers.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 21%Growth
top 28%Moat
top 45%News
top 46%Market
top 47%Talent
bottom 49%Funding: Raised $85.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Apr 2026)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 2 patents
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series C$85M
Founders & team
Investors
Orbimed
Tech stack
DiviGaugesGodaddyGoogle Font ApiHstsHttp/3
#6
Series C · Palo Alto, California · founded 2013 · 50 employees$96.4Mraised▾
Series C · Palo Alto, California · founded 2013 · 50 employees
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Moat
top 28%Innovation
top 34%Product
top 35%Growth
top 36%Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Series C (Jan 2026)
Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 82 patents · Soonicorn
Audience (LinkedIn): 10k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Associate Director of Global Quality, Senior Quality Control Manager
Funding rounds
- Jan 2026Series C$24M
- Jun 2025Series C$56M
- Jul 2024Series B$6M
- Jun 2022Venture Debt$40M
Founders & team
Investors
Viking Global Investors, Sherpalo Ventures, In-Q-Tel, Echo, Oxford Finance, SVB
Tech stack
BabelCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor
#7
Series D · San Mateo, California · founded 2020 · 24 employees$135Mraised▾
Series D · San Mateo, California · founded 2020 · 24 employees
Developer of tests for the detection and treatment of cancer and other diseases. The company's products use proteomic data with genomic, metabolomic, and other health data for early disease detection.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 17%Patents
top 25%Moat
top 28%Innovation
top 31%Talent
top 38%Tech
top 44%Funding: Raised $135M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series D (Jan 2026)
Patents: 70 patents matched (strict assignee match) · 68 filings since 2022 vs 2 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 70 patents · Soonicorn
Audience (LinkedIn): 8k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Jan 2026Series D$11.9M
- Aug 2025Series D$10M
- Aug 2024Series D$34.3M
- Mar 2022Series C$46M
Founders & team
Investors
Bruker, Catalio Capital Management, aMoon, Fidelity Investments, T. Rowe Price, Maverick Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon Web ServicesApple Icloud MailCdnjsCloudflare
#8
Acquired · Cambridge, Massachusetts · founded 2013 · 48 employees$28.9Mraised▾
Acquired · Cambridge, Massachusetts · founded 2013 · 48 employees
Developer of transformational medicines for neurological disorders. The company combines advanced human cellular models, unique measurement engineering, artificial intelligence, and machine learning into a proprietary platform to discover new drugs for neurological disease. The company's lead candidate is UBE3A for Seizure and Neurodevelopment Disorders.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 35%Market
top 50%Global
bottom 29%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) · Last round Series B (Apr 2026)
AI: Product described with: artificial intelligence, machine learning
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series B—
- Dec 2025Grant (prize money)$3M
- Jul 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.2M
Founders & team
Investors
NIH, HHS
#9
Series E · Boston, Massachusetts · founded 2013 · 103 employees$225Mraised▾
Series E · Boston, Massachusetts · founded 2013 · 103 employees
Developer of in vitro models for drug development. The company has culture modules, organ-chips, and analytical software applications. The proprietary Organ-Chip models including the liver, intestine, kidney, and others contain tiny hollow channels lined with tens of thousands of living human cells and tissues are designed to predict human response.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 15%Patents
top 25%Moat
top 26%Innovation
top 34%Tech
top 34%Growth
top 40%Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 479 patents · Soonicorn
Audience (LinkedIn): 30k LinkedIn followers — 7.7% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Business Development Executive
Funding rounds
- Sep 2025Grant (prize money)$493K
- Sep 2021Series E$82M
- Mar 2020Conventional Debt$19.3M
- Aug 2019Series C$28M
Investors
Cedars Sinai, OS Fund, ATEL Ventures, LabCorp, ALS, ND Capital
Tech stack
AddtoanyAddtoany Share ButtonsAmazon Web ServicesApple Icloud MailBackbone.JsCloudflare
#10
Series C · San Francisco, California · founded 2016 · 35 employees$107.2Mraised▾
Series C · San Francisco, California · founded 2016 · 35 employees
Provider of biomanufacturing hardware and software tools for research purposes. They have developed the digital biomanufacturing platform by integrating automated bioreactors, robotic sample handling, and cloud data monitoring. It offers services such as strain screening, media optimization, and process development.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 20%Product
top 25%Growth
top 26%Moat
top 31%Innovation
top 34%Talent
top 34%Funding: Raised $107M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Series C (Dec 2025)
Product: 6 distinct product lines · Company stage: Series C
Growth: Headcount 16 → 35 (+119%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 12k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Dec 2025Series C—
- Oct 2021Series B$80M
- Mar 2020Series A$21.6M
- Sep 2019Grant (prize money)$750K
Founders & team
Investors
Cultivian Sandbox, E14 Fund, Y Combinator, Verily, The Production Board, S32
Tech stack
CloudflareCloudflare Bot ManagementCore-JsFont AwesomeGoogle AdsGoogle Ads Conversion Tracking
#11
Series D · Boston, Massachusetts · founded 2018 · 147 employees$287.1Mraised▾
Series D · Boston, Massachusetts · founded 2018 · 147 employees
Dewpoint Therapeutics is involved in development of small molecules based therapeutics. The company offers condensate biology to create dynamic, liquid compartments in cells for the treatment of neurodegeneration, cancer, and other diseases.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 17%Moat
top 31%Talent
top 38%News
top 41%Market
top 45%Global
bottom 45%Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Sep 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 16k LinkedIn followers — 4.2% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Associate Principal / Principal Computational Biologist
Funding rounds
- Sep 2025Series D$59.1M
- Feb 2022Series C$150M
- Sep 2020Series B$77.1M
- Jan 2019Series A$60M
Founders & team
Investors
Polaris Partners, Samsara BioCapital, 6 Dimensions Capital, EcoR1, Alexandria, Leaps by Bayer
#12
Public · Freehold, New Jersey · founded 2016 · 6 employees$36.7Mraised▾
Public · Freehold, New Jersey · founded 2016 · 6 employees
Avalon GloboCare is involved in developing exosome technology. They have developed core platforms, namely Avalon Cell and Avalon Rehab for early detection of oral cancer (saliva exosomes), ovarian cancer (plasma exosomes), kidney cancer (urine exosomes), skin regeneration, anti-fibrosis, treatments of degenerative disorders such as Alzheimer’s disease, arthritis, osteoporosis, etc.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
News
top 26%Funding
top 34%Patents
top 45%Growth
top 47%Innovation
bottom 48%Moat
bottom 44%News: 14 BI events in 12 mo (of 21 tracked, 5 types) · 9 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: M&A, Announcements, Acquisition
Funding: Raised $36.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Post IPO (Feb 2026)
Patents: 16 patents matched (strict assignee match) · 8 filings since 2022 vs 8 in 2017-21 · Latest publication 2024
Funding rounds
- Feb 2026Post IPO$3.2M
- Oct 2023Post IPO$700K
- Dec 2022Post IPO$4M
- Sep 2019Conventional Debt$20M
Investors
Falcon Capital, PagodaTree Partners
Tech stack
Apache Http ServerBootstrapCore-JsFacebook PixelFancyboxGodaddy
Funding & investor landscape
$32.9Btotal disclosed funding
1,365companies funded
6,282disclosed rounds
10rounds last 90 days
Most active investors
Y Combinator34 rounds
Notable founders
Fabian Gerlinghaus
Co-Founder & CEO · Cellares
Omar Kurdi
Co-Founder · Cellares
Steve Chen
Co-Founder · Alamar Biosciences
Yuling Luo
Co-Founder & CEO · Alamar Biosciences
James Atwood
CEO · Opentrons
Jonathan Brennan-Badal
CEO · Opentrons
John Zehner
CEO · SpectronRx
Christina Smolke
Co-Founder & CEO · Antheia
Kristy Hawkins
Co-Founder & CSO · Antheia
Philip Ma
Co-Founder & CEO · PrognomiQ
Omid Farokhzad
Co-Founder · PrognomiQ
Paul Roma
Co-Founder · Quiver Bioscience
Prism market signals · United States · country-scoped Prism corpus, 1,926,398 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
research sentiment over time
200820182029
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 41% → 46% across 2008–2029.
top research entities
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
leading researchers
Glen Charles Ritschel · Claude · Stylianos Chatzimanolis · Giannis Bolanakis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Yue Ma
▲
Breakthroughs5,029 · 38%
▼ 39%→38% share
▲1.0× share momentum0 median citations85% since 2021mostly methods-led
Transcriptome breakthroughs are surging — U.S. papers rose from 25 to 436, with interpretability emerging as a brand-new focus.
rising sub-themes (early→recent)
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
Newly emergingPattern recognition (psychology) 0→57 · Interpretability 0→50 · Limiting 0→47
Landmark Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 97,164 cites
◆
Advancements3,749 · 29%
▲ 21%→30% share
▲1.4× share momentum0 median citations90% since 2021mostly empirical
Biomarker advancements are intensifying — papers jumped from 2 to 208, alongside newly emerging precision medicine research (86 papers).
rising sub-themes (early→recent)
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
Newly emergingPrecision medicine 0→86 · Pathogenesis 0→49 · Receptor 0→42
Landmark limma powers differential expression analyses for RNA-sequencing and microarray studies · 41,828 cites
▼
Concerns2,105 · 16%
▼ 18%→16% share
▼0.9× share momentum0 median citations85% since 2021mostly reviews
Clinical-trial concerns are escalating — papers grew from 4 to 111, with immunotherapy newly flagged as a concern (56 papers).
rising sub-themes (early→recent)
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Newly emergingImmunotherapy 0→56 · Narrative review 0→36 · Mutation 0→33
Landmark The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia · 10,090 cites
RESEARCH HOTSPOTS · United States
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1143 · +0.51
New York807 · +0.46
SF Bay Area683 · +0.57
Philadelphia330 · +0.44
San Diego298 · +0.56
Los Angeles287 · +0.42
Chicago284 · +0.51
Seattle244 · +0.54
Ann Arbor218 · +0.45
Atlanta215 · +0.44
PATENT SIGNAL · United States
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
246 filings64 assigneespeak 44/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat5
Common questions
How many Life Sciences Platforms and Tools companies are there in United States?
Radar tracks 2973 indexable Life Sciences Platforms and Tools companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences Platforms and Tools companies in United States?
The Life Sciences Platforms and Tools companies in United States on this list have raised a combined $32.9B in disclosed equity funding across 1365 funded companies.
Which is the highest-funded Life Sciences Platforms and Tools company in United States?
Nektar is the highest-funded Life Sciences Platforms and Tools company in United States, with $905M in disclosed equity funding.
How many Life Sciences Platforms and Tools companies in United States are funded?
1365 of the 2973 Life Sciences Platforms and Tools companies in United States on this list have disclosed at least one equity funding round.
How many Life Sciences Platforms and Tools unicorns are there in United States?
3 Life Sciences Platforms and Tools companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Life Sciences Platforms and Tools companies?
The most active investors in United States Life Sciences Platforms and Tools companies on this list include HHS, National Science Foundation, NIH, America’s Seed Fund, Europa.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.